Serial No.: 10/538,452 Filed: June 10, 2005 Page: 3 of 10

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of formula (I):

R¹ is independently hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl;

 R^2 is independently aryl, heteroaryl or a group C_{1-6} alkyl R^9 , $CO(C_{1-6}$ alkyl) R^9 or $SO_2(C_{1-6}$ alkyl) R^9 ; where R^9 is aryl or heteroaryl;

or R^1 and R^2 together with the nitrogen atom to which they are attached form a 4 to 7-membered saturated ring optionally containing a carbonyl group, O, S or N atom and optionally substituted by one or more C_{1-6} alkyl, amino, hydroxy, CO_2C_{1-6} alkyl, COC_{1-6} alkyl, halogen, C_{1-6} alkylhydroxy, $NR^{10}R^{11}$ where R^{10} and R^{11} are independently hydrogen, C_{1-6} alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^1 group, C_{1-6} alkyl $NR^{12}R^{13}$ where R^{12} and R^{13} are independently hydrogen or C_{1-6} alkyl, $CONR^{12}R^{13}$, or optionally substituted by C_{1-6} alkyl R^9 , aryl, phenoxy, CO aryl, CO heteroaryl or a heteroaryl group, the latter six groups being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, $CONR^{12}R^{13}$, $SO_2NR^{12}R^{13}$, SO_2R^{12} , trifluoromethyl, $NHSO_2R^{12}$, $NHCOR^{12}$, ethylenedioxy, methylenedioxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkyl $NR^{10}R^{11}$, SR^{12} or $NR^{10}R^{11}$;

Het is a heteroaryl ring chosen from pyridine, pyrimidine, pyrazine, pyridazine or triazine and optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, $CONR^{12}R^{13}$, $SO_2NR^{12}R^{13}$, SO_2R^{12} , trifluoromethyl, $NHSO_2R^{12}$, $NHCOR^{12}$, C_{1-6} alkyl, C_{1-6} alkoxy, SR^{12} or $NR^{10}R^{11}$;

Serial No.: 10/538,452 Filed: June 10, 2005 Page: 4 of 10

R³ is independently hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl;

 R^4 is independently hydrogen, C_{1-8} alkyl, C_{3-8} cycloalkyl, aryl C_{1-5} alkyl or heteroaryl C_{1-5} alkyl, the latter three groups being optionally substituted by one or more halogen, amino, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, SR^{12} or $NR^{10}R^{11}$;

 R^5 is independently hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

R⁶ is independently hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl;

R⁷ is independently hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl; and

 R^8 is independently hydrogen, aryl, heteroaryl or $C_{1\text{-}6}$ alkyl optionally substituted with one or more aryl, heteroaryl, halogen, amino, hydroxy, carboxy, $CONR^{12}R^{13}$, $SO_2NR^{12}R^{13}$, SO_2R^{12} , $NHSO_2R^{12}$, $NHCOR^{12}$, $C_{1\text{-}6}$ alkyl, $C_{3\text{-}6}$ cycloalkyl, $C_{1\text{-}6}$ alkoxy, SR^{12} or $NR^{10}R^{11}$; or a pharmaceutically acceptable salt thereof.

- 2. (Withdrawn) A compound according to claim 1 in which R^1 is hydrogen or C_{1-6} alkyl and R^2 is CH_2R^9 or $CH_2CH_2R^9$ where R^9 is phenyl or a 5- or 6-membered aromatic ring containing one or two heteroatoms and optionally substituted by C_{1-6} alkyl.
- 3. (Previously Presented) A compound according to claim 1 in which R¹ and R² together with the nitrogen atom to which they are attached form a piperidine, piperazine, pyrrolidine, morpholine, or thiomorpholine ring optionally substituted by CH₂OH, CH₂CH₂OH, hydroxy, CONH₂, phenyl, phenoxy, or C(O)-furyl, the latter three groups being optionally substituted by halogen, in particular chloro.
- 4. (Previously Presented) A compound according to claim 1 in which R³ is hydrogen.
- 5. (Previously Presented) A compound according to claim 1 in which R⁴ is hydrogen.
- 6. (Previously Presented) A compound according to claim 1 in which R^5 is hydrogen or phenyl optionally substituted by C_{1-6} alkyl or C_{1-6} alkoxy.

Serial No.: 10/538,452 Filed: June 10, 2005 Page: 5 of 10

7. (Currently Amended) A compound of formula (I) selected from:

 $N\sim1\sim-[Cyano(2-methoxyphenyl)methyl]-N\sim2\sim-(2-morpholin-4-ylpyrimidin-4-yl)-L-leucinamide,$

 $N\sim 1\sim -[Cyano(2-methoxyphenyl)methyl]-N\sim 2\sim -(2-piperazin-1-ylpyrimidin-4-yl)-L-leucinamide,$

N-[Cyano(2-methoxyphenyl)methyl]-N-(2-morpholin-4-ylpyrimidin-4-yl)-L-phenylalaninamide,

N~1~-[Cyano(2-methoxyphenyl)methyl]-3-cyclohexyl-N~2~-(2-morpholin-4-ylpyrimidin-4-yl)-L-alaninamide,

N-[2-(Benzylamino)pyrimidin-4-yl]-N-(cyanomethyl)-L-phenylalaninamide,

N-{2-[Benzyl(methyl)amino]pyrimidin-4-yl}-N-(cyanomethyl)-L-phenylalaninamide,

 $N-\{2-[4-(4-Chlorophenyl)piperazin-1-yl]pyrimidin-4-yl\}-N-(cyanomethyl)-L-phenylalaninamide,\\$

 $N\sim2\sim-[2-(Benzylamino)pyrimidin-4-yl]-N\sim1\sim-(cyanomethyl)-3-cyclohexyl-L-alaninamide,$

 $N\sim2\sim-\{2-[Benzyl(methyl)amino]$ pyrimidin-4-yl $\}-N\sim1\sim-(cyanomethyl)-3-cyclohexyl-L-alaninamide,$

 $N\sim2\sim-\{2-[4-(4-Chlorophenyl)piperazin-1-yl]pyrimidin-4-yl\}-N\sim1\sim-(cyanomethyl)-3-cyclohexyl-L-alaninamide,$

N~1~-(Cyanomethyl)-N~2~-(4-morpholin-4-ylpyrimidin-2-yl)-L-leucinamide,

N~1~-(Cyanomethyl)-N~2~-(2-morpholin-4-ylpyrimidin-4-yl)-L-leucinamide,

 $N\sim 1\sim -(Cyanomethyl)-N\sim 2\sim -[2-(4-hydroxy-4-phenylpiperidin-1-yl)pyrimidin-4-yl]-L-leucinamide,$

 $N\sim1\sim-(Cyanomethyl)-N\sim2\sim-\{2-[methyl(pyridin-3-ylmethyl)amino]pyrimidin-4-yl\}-L-leucinamide,$

N~2~-{2-[Benzyl(methyl)amino]pyrimidin-4-yl}-N~1~-(cyanomethyl)-L-leucinamide,

 $N\sim2\sim-\{2-[4-(4-Chlorophenyl)piperazin-1-yl]pyrimidin-4-yl\}-N\sim1\sim-(cyanomethyl)-L-leucinamide,$

 $N\sim2\sim-\{2-[4-(5-Chloropyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl\}-N\sim1\sim-(cyanomethyl)-L-leucinamide,$

Serial No.: 10/538,452 Filed: June 10, 2005 Page: 6 of 10

 $N\sim1\sim-(Cyanomethyl)-N\sim2\sim-\{2-[methyl(thien-3-ylmethyl)amino]pyrimidin-4-yl\}-L-leucinamide,$

N~1~-(Cyanomethyl)-N~2~-(2-thiomorpholin-4-ylpyrimidin-4-yl)-L-leucinamide,

N~1~-(Cyanomethyl)-N~2~-[2-(4-phenylpiperazin-1-yl)pyrimidin-4-yl]-L-leucinamide,

 $N\sim 1\sim -(Cyanomethyl)-N\sim 2\sim -\{2-[2-(hydroxymethyl)piperidin-1-yl]pyrimidin-4-yl\}-L-leucinamide,$

 $N\sim1\sim-(Cyanomethyl)-N\sim2\sim-\{2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]pyrimidin-4-yl\}-L-leucinamide,$

N~1~-(Cyanomethyl)-N~2~-[2-(4-hydroxypiperidin-1-yl)pyrimidin-4-yl]-L-leucinamide,

 $N\sim 1\sim -(Cyanomethyl)-N\sim 2\sim -\{2-[4-(2-furoyl)piperazin-1-yl]pyrimidin-4-yl\}-L-leucinamide,$

N~2~-{2-[3-(Aminocarbonyl)piperidin-1-yl]pyrimidin-4-yl}-N~1~-(cyanomethyl)-L-leucinamide,

 $N\sim1\sim-(Cyanomethyl)-N\sim2\sim-\{2-[methyl(2-pyridin-2-ylethyl)amino]pyrimidin-4-yl\}-L-leucinamide,$

N~2~-[2-(4-Benzylpiperidin-1-yl)pyrimidin-4-yl]-N~1~-(cyanomethyl)-L-leucinamide, N~1~-(Cyanomethyl)-N~2~-[2-(4-pyridin-2-ylpiperazin-1-yl)pyrimidin-4-yl]-L-leucinamide,

 $\label{eq:n-1} N~1~-(Cyanomethyl)-N~2~-[2-(4-phenylpiperidin-1-yl)pyrimidin-4-yl]-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl\}-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl\}-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl\}-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl\}-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl\}-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl\}-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl\}-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl]-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl]-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-\{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl]-L-leucinamide, $N~1~-(Cyanomethyl)-N~2~-(Cya$

leucinamide,

 $N\sim2\sim-\{2-[4-(3-Chlorophenyl)piperazin-1-yl]pyrimidin-4-yl\}-N\sim1\sim-(cyanomethyl)-L-leucinamide,$

N~1~-(Cyanomethyl)-N~2~-[2-(4-phenoxypiperidin-1-yl)pyrimidin-4-yl]-L-leucinamide,

 $N\sim 1\sim -(Cyanomethyl)-N\sim 2\sim -[2-(3-phenylpyrrolidin-1-yl)pyrimidin-4-yl]-L-leucinamide,$

 $N\sim1\sim-(Cyanomethyl)-N\sim2\sim-(2-\{methyl[(3-methylisoxazol-5-yl)methyl]amino\}$ pyrimidin-4-yl)-L-leucinamide,

and pharmaceutically acceptable salts thereof.

8. (Canceled)

Serial No.: 10/538,452 Filed: June 10, 2005 Page: 7 of 10

9. (Previously Presented) A pharmaceutical composition which comprises a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

10. (Cancelled)

- 11. (Withdrawn) A method for treating pain, such as neuropathic pain, in a mammal, such as man, in need of such treatment, which comprises administering to said mammal an effective amount of a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.
- 12. (Previously Presented) A pharmaceutical composition which comprises a compound according to claim 7 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

13. (Cancelled)

- 14. (Withdrawn) A method for treating pain, such as neuropathic pain, in a mammal, such as man, in need of such treatment, which comprises administering to said mammal an effective amount of a compound according to claim 7, or a pharmaceutically acceptable salt thereof.
 - 15. (Withdrawn) A compound according to claim 2 in which R³ is hydrogen.
 - 16. (Withdrawn) A compound according to claim 2 in which R⁴ is hydrogen.
- 17. (Withdrawn) A compound according to claim 2 in which R^5 is hydrogen or phenyl optionally substituted by C_{1-6} alkyl or C_{1-6} alkoxy.

Serial No. : 10/538,452 Filed : June 10, 2005 Page : 8 of 10

18. (Previously Presented) A compound according to claim 3 in which R³ is hydrogen.

- 19. (Previously Presented) A compound according to claim 3 in which R^4 is hydrogen.
- 20. (Previously Presented) A compound according to claim 3 in which R^5 is hydrogen or phenyl optionally substituted by C_{1-6} alkyl or C_{1-6} alkoxy.